SynthesisJournal of neuro-oncology2026
cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes.
Synthesis in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
Abstract
background/purposeGlioblastoma (GBM) is characterized by an immunosuppressive tumor microenvironment and poor responsiveness to immune checkpoint blockade, driving interest in cGAS-STING pathway activation to stimulate antitumor immunity. We performed a systematic review of preclinical in vivo studies evaluating STING agonists in glioblastoma, with emphasis on immune microenvironment effects and survival outcomes.
methodsA systematic review of PubMed, Cochrane, and Embase was conducted through February 2025 following PRISMA guidelines. Studies were included if they evaluated STING agonists in live animal models of GBM and reported survival outcomes or tumor microenvironment changes. Two reviewers independently screened studies and extracted data. Risk of bias was assessed qualitatively based on study design and reporting characteristics. Given heterogeneity in models, treatments, and outcomes, results were synthesized descriptively.
resultsFourteen studies met the inclusion criteria, spanning synthetic and natural cyclic dinucleotides and non-cyclic STING agonists. Across diverse delivery methods, including intracranial injection, hydrogels, and nanoparticle systems, STING agonists were associated with increased CD8 + T-cell and NK cell infiltration and repolarization of tumor-associated macrophages toward pro-inflammatory phenotypes. Several studies reported prolonged survival, including long-term tumor clearance in select models. Combination therapies with immune checkpoint inhibitors or radiotherapy showed synergistic effects in some studies.
conclusionsSTING agonists can enhance anti-tumor immune responses and prolong survival in preclinical GBM models by promoting cytotoxic lymphocyte recruitment and remodeling the tumor-associated myeloid landscape. However, translation remains challenging due to limitations of current models, the limited clinical traction STING modulation has thus far achieved in other cancer types, incomplete understanding of cell-type-specific STING activation in the brain, and the possibility that sustained STING signaling may drive maladaptive inflammation rather than durable antitumor immunity.
Indexed as
Identifiers
42101774What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.